medigraphic.com
ISSN 1561-3186 (Electronic)

2020, Number 1

<< Back Next >>

Rev Acta Médica 2020; 21 (1)

Characterization of symptomatic patients with metastatic prostate cancer and hormonal castration resistance

Caballero AI, Varona RLM, Robaina GM, Crombet RT, García GA, Mendoza HI, Artiles MAJ, Sánchez RI

Language: Spanish
References: 32
Page: 1-17
PDF size: 338.11 Kb.


ABSTRACT

Introduction: 15-25% of patients with prostate cancer develop hormonal castration resistance within the first 5 years after the diagnosis; of these, more than 80% have metastatic disease.
Objective: To characterize the clinical evolution, treatment and overall survival, as well as the clinical and biochemical response of patients with metastatic prostate cancer and hormonal castration resistance.
Methods: A descriptive, longitudinal and retrospective study was carried out with a sample of 137 symptomatic, metastatic patients with hormonal castration resistance and treated at Hermanos Ameijeiras Clinical-Surgical Hospital between 2006 and 2015. We estimated the overall survival and the clinical and biochemical progression time, according to an 95% CI associated with the Kaplan-Meier estimator.
Results: The mean age was 63 years and 81.4% had bone metastases. The mean time for starting chemotherapy was 1.5 years shorter in patients with Gleason index lower than 8 according to biopsy (p = 0.02), and initial PSA higher than 20 ng/mL. The median overall survival was 13.2 months and was higher in those who received chemotherapy with docetaxel-prednisone-nimotuzumab (19.2 months).
Conclusions: This study permitted to realize the benefit of chemotherapy in overall survival, pain control, and clinical and biochemical recurrence time. The results obtained from the so-called "true world" may contribute to the identification of biomarkers and the introduction of new drugs, such as nimotuzumab, in future clinical studies.


REFERENCES

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics. J Clin. 2013 [Acceso 25/01/2018];63(1):11-30. Disponible en: https://www.ncbi.nlm.nih.gov › pubmed

  2. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012 [Acceso 25/01/2018];61:1079-1092. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22424666

  3. Ahmedin J, Freddie B, Melissa M, et al. Global Cancer Statistics. J Clin. 2011;61:69-90.

  4. Ministerio de Salud Pública; Dirección Nacional de Estadística; Cuba. Anuario estadístico de salud. La Habana: MINSAP/DNE; 2016.

  5. Taichman R, Loberg R, Mehra R, et al. The evolving biology and treatment of prostate cancer. J Clin Invest. 2007 [Acceso 25/01/2018];117:2351-2361. Disponible en: https://www.ncbi.nlm.nih.gov › pubmed

  6. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. V.1. 2018. National Comprehensive Cancer Network. [Acceso 25/01/2018] Disponible en: http://www.nccn.org

  7. Kirby M, Hirst C, Crawford ED. Characterizing the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011 [Acceso 25/01/2018];65:1180-1192. Disponible en: https://www.ncbi.nlm.nih.gov › pubmed

  8. Shiota M, Yokomizo A, Fujimoto N, et al. Castration-resistant prostate cancer: novel therapeutics pre- or post-taxane administration. Curr Cancer Drug Targets. 2013 [Acceso 25/01/2018];13:444-595. Disponible en: https://www.ncbi.nlm.nih.gov › articles › PMC4707543

  9. Tannock IF, de Wit R, Berry WR, et al. On behalf of the TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 [Acceso 25/01/2018];351:1502-12. Disponible en: https://www.ncbi. nlm.nih.gov › pubmed

  10. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 [Acceso 25/01/2018];351:1513-20. Disponible en: https://www.nejm.org › 10.1056 › NEJMoa041318

  11. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone‑resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol. 1996 [Acceso 25/01/2018];14:1756-64. Disponible en: https://www.ncbi.nlm.nih.gov › pubmed

  12. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology. 1995 [Acceso 25/01/2018];46(2);142-148. Disponible en: https://link.springer.com › article

  13. Osoba D, Tannock IF, Ernst DS, et al. Health‑related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999 [Acceso 25/01/2018];17:1654-63. Disponible en: https://www.ncbi.nlm.nih.gov › pubmed

  14. Basch, et al. Systemic Therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. JCO. 2013 [Acceso 25/01/2018];54:8404. Disponible en: https://ascopubs.org › doi › JCO.2013.54.8404

  15. Andrew J, et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol. 2012 [Acceso 25/01/2018];61(3):549-559. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov › articles › PMC3445625

  16. Matthew R, et al. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2011 May;15;117(10). doi: 10.1002/cncr.25762. Epub 2015 Nov 16 https://www.ncbi.nlm.nih.gov › pubmed

  17. Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, et al. Randomized phase ii study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 [Acceso 25/01/2018];28:4247-4254. Disponible en: https://www.ncbi.nlm.nih.gov › pubmed

  18. Armstrong AJ, Tannock IF, de Wit R, et al. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer. 2010 [Acceso 25/01/2018];46:517-25. Disponible en: https://www.ncbi.nlm.nih.gov › articles › PMC6888025

  19. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999 [Acceso 25/01/2018];17:2506-2513. Disponible en: https://www.ncbi.nlm.nih.gov › pubmed

  20. Huang Xiao-dong, Xu Guo-Zhen, et al. Phase Ⅱ clinical trial of h-R3, the recombined humanized anti-epidermal factor receptor monoclonal antibody, in combination with radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Chin J Oncol. 2007 [Acceso 25/01/2018];29(3):197-201. Disponible en: https://www.ncbi. nlm.nih.gov › pubmed

  21. Susan H, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2015 [Acceso 25/01/2018];32:671-677. Disponible en: https://www.ncbi.nlm.nih.gov › pubmed

  22. Kazuhiko N, et al. External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer. BMC Urology. 2014 [Acceso 25/01/2018];14:31. Disponible en: https://www.ncbi.nlm.nih.gov › articles › PMC3997751

  23. Berry DL, Moinpour CM, Jiang CS, Ankerst DP, Petrylak DP, Vinson LV, et al. Quality of life and pain in advanced stage prostate cancer: Results of a southwest oncology group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol. 2006 Jun 20 [Acceso 25/01/2018];24(18):2828-35. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/16782921

  24. Arun A, et al. A retrospective canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. The Prostate. 2014 [Acceso 25/01/2018];74:1544-1550. Disponible en: www.researchgate.net/publication

  25. Masaki S, et al. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer. Jan J Clin Oncol. 2014 [Acceso 25/01/2018];44(9)860-867. Disponible en: https://www.ncbi.nlm.nih.gov › pubmed

  26. Horgan AM, Seruga B, Pond GR, Alibhai SM, Amir E, De Wit R, et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol. 2014 [Acceso 25/01/2018];5(2):119-126. Disponible en: https://www.ncbi.nlm.nih.gov › pubmed

  27. Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold L, Berry WR, et al. Evaluating the value of number of cycles of docetaxel prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol. 2012 [Acceso 25/01/2018];61(2):363-369. Disponible en: https://www.ncbi.nlm.nih.gov › pubmed

  28. Gupta E, Guthrie T, Tan W, et al. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). BMC Urology. 2014;14:55. https://pubs.acs.org › DOI: 10.1186/1471-2490-14-55.

  29. Susan Halabi, Andrew J. Armstrong, Ellen Kaplan, Chen-Yen Lin, and Nicole. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol. 2016 [Acceso 25/01/2018];31:3944-3950. Disponible en: https://www.ncbi.nlm.nih.gov › pubmed

  30. Tomioka A, Tanaka N, Yoshikawa M, Miyake M, Anai S, Chihara Y, et al. Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer. BMC Urology. 2014 [Acceso 25/01/2018];14:33. Disponible en: https://www.ncbi.nlm.nih.gov › articles › PMC4018264

  31. Andrew J, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2017 [Acceso 25/01/2018];25:3965-3970. Disponible en: https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.30587

  32. Andrew J. Armstrong, Fred Saad, De Phung, Carl Dmuchowski, Neal D. Shore, Karim Fizazi, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2016 [Acceso 25/01/2018];27:2450-2456. Disponible en: https://onlinelibrary.wiley.com › doi › pdf › cncr




2020     |     www.medigraphic.com